aspirin

She was initially treated with low-dose acetylsalicylic acid, with partial improvement, but microvascular symptoms persisted, and platelet counts remained >1,000 × 10⁹/L. Hydroxyurea was initiated, leading to progressive platelet reduction and marked clinical benefit...Cytoreductive therapy may be indicated in cases with extreme thrombocytosis or refractory symptoms, and long-term follow-up is crucial to monitor disease evolution and treatment outcomes. This case highlights the need for multicenter studies and international registries to have pediatric-specific evidence that can better inform diagnostic and therapeutic strategies.

P1, N=161, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026

Aspirin suppressed the malignant progression of osteosarcoma by targeting the NF-κB/p65/PDE4D axis, positioning PDE4D as a potential therapeutic target for aspirin- based treatment strategies.

P2, N=117, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Jun 2026

P2/3, N=670, Not yet recruiting, Stanford University

P4, N=970, Completed, Beijing Tiantan Hospital | Recruiting --> Completed | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Feb 2025

DSigDB database analysis revealed four possible therapeutic drugs for pancreatic cancer: prolinedithiocarbamate, isoliquiritigenin, aspirin, and resveratrol...High-risk pancreatic cancer populations are potentially associated with an immunosuppressive microenvironment. Candidate drugs screened based on LMRGs offer new possibilities for personalized treatment of pancreatic cancer.

The ability to downregulate these cytokines was close to that of aspirin and stronger than that of low concentration LR-AFY02L. By controlling the NF-κB and apoptosis pathways, LR-AFY02 can help reduce intestinal inflammation and prevent the growth of intestinal tumors. These findings suggested that LR-AFY02 may have regulatory effects on colon cancer in mice and merits additional study.

P1, N=100, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Jul 2026

P=N/A, N=100, Not yet recruiting, Mayo Clinic | Trial completion date: Aug 2026 --> Dec 2027 | Initiation date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2027

Treatment comprised phlebotomy, low-dose aspirin, hydroxyurea, and statin therapy. Ischemic stroke can be the initial presentation of JAK2-positive erythrocytosis consistent with polycythemia vera. Careful framing of diagnostic certainty, early hematocrit control, antithrombotic therapy, and risk-factor optimization are key, especially where resources are limited.

P=N/A, N=21194, Not yet recruiting, Queen Mary University of London | Initiation date: Sep 2025 --> Aug 2026 | Trial primary completion date: Apr 2028 --> Oct 2027